Yaman Walid Kassab

Dr. Yaman Walid Kassab

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
CNChun Zheng Ng
Chun Zheng Ng
YLYen Loong Lean
Yen Loong Lean
SYSiang Fei Yeoh
Siang Fei Yeoh
QLQi Ying Lean
Qi Ying Lean
KLKah Seng Lee
Kah Seng Lee
Long MingLong Ming
Long Ming
Ng CZ, et al. Clin Exp Vaccine Res. 2020 Jan;9(1):8-14. https://doi.org/10.7774/cevr.2020.9.1.8

1 January 2013 in International Journal of Low Radiation
Verified
Journal Article
Closed access
MJMohammed Husham Al Janabi
Mohammed Husham Al Janabi
MJMohamad Suhaimi Jaafar
Mohamad Suhaimi Jaafar
ARAsmiet Ramizy
Asmiet Ramizy
KOKhalid Omar
Khalid Omar
YKYaman Walid Kassab
Yaman Walid Kassab
The indoor radon gas released from concrete was measured using a 0.65 × 0.65 × 0.65 m fabricated concrete slab room, simulating a workplace. The indoor radon gas concentration was monitored, and the remediation method was examined. Radon concentrations were monitored using Radon Monitor Model 1023 from Sun Nuclear. Results show that average radon concentrations reached 111 Bq.m

Verified
Journal Article
Open access
PDF file
NSNajah abdullah Salmi
Najah abdullah Salmi
BSBushra Salman
Bushra Salman
YKYaman Walid Kassab
Yaman Walid Kassab
SZShireen Imam Bakhsh Al Zadjali
Shireen Imam Bakhsh Al Zadjali
MBMULLAICHARAM BHUPATHYRAAJ
MULLAICHARAM BHUPATHYRAAJ
Salam AlKindiSalam AlKindi
Salam AlKindi
Background: Myeloproliferative neoplasms (MPNs)—including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)—are clonal stem-cell disorders driven by JAK–STAT pathway activation within an inflammatory microenvironment. Ruxolitinib (RUX), a JAK1/2 inhibitor, improves splenomegaly and symptom burden in myelofibrosis and serves as second-line therapy in hydroxyurea-resistant/intolerant PV. However, real-world data from Middle Eastern populations remains scarce. This study evaluates the effectiveness, safety, and dosing practices of RUX in a heterogeneous Omani MPN cohort. Methods: Electronic records were reviewed for adults diagnosed with MF, PV, or ET who received RUX at Sultan Qaboos University Hospital or the National Hematology and BMT Center between 2018 and 2025. Only patients with at least six months of follow-up were included. Clinical variables, laboratory results, dosing information, and data on treatment responses and toxicities were extracted. Outcomes focused on spleen size changes, symptom improvement, hematologic responses, adverse events, and reasons for treatment discontinuation. Results: Twenty-eight patients were included (71% PMF; mean age 52.6 years). The median time from diagnosis to RUX initiation was 28 months. Among MF patients, mean spleen size decreased by 35% (p = 0.003); 28% achieved ≥35% reduction. Symptomatic improvement was reported by 60%. LDH levels remained unchanged. PV patients showed spleen control in 75% and symptom benefit in all cases, while ET responses were limited. Cytopenias (21%) and infections (11%) were the most common toxicities; discontinuation occurred in 8/28 of patients, and two patients died while on therapy. Initial dosing was frequently inappropriate, particularly underdosing in MF and overdosing in PV. Conclusions: RUX provided meaningful spleen and symptom improvement in MF and PV; however, toxicity, delayed initiation, and inconsistent dosing practices limited overall outcomes. Enhanced guideline-based dosing, proactive toxicity management, and structured multidisciplinary follow-up are essential to optimize RUX use in regional MPN practice.

23 July 2026 in Journal of Emergency Medicine, Trauma and Acute Care
Verified
Journal Article
Open access
AAAhlam Omar AlRashdi
Ahlam Omar AlRashdi
YAYahya Alwahshi
Yahya Alwahshi
YKYaman Walid Kassab
Yaman Walid Kassab
ANAbdul Salam Nazmi
Abdul Salam Nazmi
Objectives: Sacubitril/valsartan has shown benefits in managing heart failure with reduced ejection fraction (HFrEF). However, more data on its effectiveness and safety in diverse populations is needed. This study evaluated its long-term effects on echocardiographic and clinical parameters of heart function and reverse cardiac remodeling in Omani patients with HFrEF, with an emphasis on gender-related differences. Methods: This retrospective cohort study was conducted at a tertiary hospital in Oman from January 2018 to December 2023. Data were collected through retrospective chart reviews and follow-up assessments conducted 12 months after initial assessment. Results: Among the patients, 72.5% were male, with a mean age of 60.1 ± 11.4 years. Significant improvements were observed in systolic blood pressure (137.7 ± 19.38 to 131.59 ± 19.23 mmHg, p = 0.013), diastolic blood pressure (80 to 74.5 mmHg, p < 0.001), heart failure class (2 to 1, p < 0.001), left ventricular ejection fraction (31% to 37%, p < 0.001), end-systolic volume (112.69 ± 37.78 mL, p = 0.011), and left atrium diameter (4.1 to 4 cm, p = 0.002). Female patients experienced greater treatment benefits. No association was found between reverse cardiac remodeling and gender or comorbidities. Conclusion: Sacubitril/valsartan demonstrated significant benefits in managing HFrEF in Omani patients. Gender differences in response highlight the need for personalized treatment strategies.

28 December 2021 in Journal of Pharmaceutical Research International
Verified
Journal Article
Open access
PDF file
YKYaman Walid Kassab
Yaman Walid Kassab
ASAmra Salahuddin
Amra Salahuddin
MMMuhammad Umer Abdul Moiz
Muhammad Umer Abdul Moiz
SKSyed Haroon Khalid
Syed Haroon Khalid
AEAbdullah Ehsan
Abdullah Ehsan
MIMuhammad Shahid Iqbal
Muhammad Shahid Iqbal
Background: This study aimed to assess attitude of cardiac patients about Coenzyme Q10 supplements. Methods: A cross-sectional study using convenience sampling based on inclusion and exclusion criteria was conducted among cardiac patients. This study was conducted using a self-administered questionnaire, derived from extensive literature reviews. Results: Study subjects were found to have average attitude (n= 87, 64.9%) towards Coenzyme Q10 supplementations. This study found strong positive correlation between the knowledge score and attitude score (r=0.776, p<0.05). It was found that 7 (46.67%) of study subjects who consumed the Coenzyme Q10 supplements were recommended by friends and family. Conclusion: The attitude towards Coenzyme Q10 supplements reflected the low pattern of use, and emphasized the role of healthcare providers to increase awareness about the benefits of Coenzyme Q10 supplements among cardiac patients as well as to educate them about its interaction with some drugs.

28 December 2021 in Journal of Pharmaceutical Research International
Verified
Journal Article
Open access
PDF file
YKYaman Walid Kassab
Yaman Walid Kassab
ASAmra Salahuddin
Amra Salahuddin
MMMuhammad Umer Abdul Moiz
Muhammad Umer Abdul Moiz
SKSyed Haroon Khalid
Syed Haroon Khalid
AEAbdullah Ehsan
Abdullah Ehsan
MIMuhammad Shahid Iqbal
Muhammad Shahid Iqbal
Background: Most studies showed fair evidence on the benefits of Coenzyme Q10 supplements in improving cardiac functions and preventing cardiovascular diseases. This study aimed to assess knowledge of Coenzyme Q10 supplements among cardiac patients. Methods: This was a cross-sectional study and 134 patients were conveniently enrolled based on inclusion and exclusion criteria. This study was conducted using a self-administered questionnaire, derived from extensive literature reviews. Results: Study subjects were found to have not appropriate knowledge about Coenzyme Q10 supplements (mean knowledge score=1.8, SD=3.131). This study found strong positive correlation between the knowledge score and attitude score (r=0.776, p<0.05). Elderly and those earning higher incomes had statistically higher knowledge scores compared to others. Conclusion: The obtained knowledge towards Coenzyme Q10 supplements reflected the low pattern of use among cardiac patients. It also emphasized the role of healthcare providers to increase awareness about the benefits of Coenzyme Q10 supplements among cardiac patients as well as to educate them about its interaction with some drugs.